Kadakia K, Dhruva S, Ross J, Burke J, Johnston J, Ramachandran R, Krumholz H , Rathi V
Summary: Retatrutide can cause a dose-dependent increase in resting heart rate, with Phase 2 trials reporting mean rises of approximately 5 to 7 beats per minute at higher doses, likely driven by its GLP-1 and glucagon receptor agonism
Interestingly, it has been reported that Pdcd4 is phosphorylated at Ser67 by p70S6K and followed by proteasomal degradation
The judges ruling will influence how much evidence juries in this and future Paragard cases can consider when evaluating the manufacturers conduct and punitive damages
Even at low doses, these medications carry risks including pancreatitis (requiring discontinuation if suspected), gallbladder disease, and rare but serious adverse events such as medullary thyroid carcinoma (boxed warning